Determination And Clinical Significance Of Serum TL1A And IL-17Levels In Rheumatoid Arthritis Patients Treated With Etanercept

Objectives1. To analysis the clinical significance of serum TL1A and IL-17levels in rheumatoidarthritis （RA）.2. To evaluate the impact of Etanercept in serum TL1A and IL-17levels in RApatients, and its relation to clinical efficacy.3. To evaluate the feasibility of serum TL1A and IL-17levels predicting the efficacyof Etanercept in RA patients.Method1. Collected50RA patients and healthy volunteers respectively, the level of serumTL1A and IL-17was measured by Enzyme-linked immunosorbent assay （ELISA）,the laboratory data（C-reactive Protein （CRP）, erythrocyte sedimentation rate （ESR）,and rheumatoid factors （RF）） and clinical data （the swollen joint count （SJC）,tender joint count （TJC） and visual analog scale method （VAS）） were alsomeasured and observed. Disease activity score28（DAS28） at baseline of patientswas calculated according to the formula(DAS28=0.56×TJC^1/2+0.28×SJC^1/2+0.7×ln（ESR）+0.014VAS).The correlation between the level of serum TL1A, IL-17and the data of laboratoryand clinical was analyzed.2. RA patients were treated with twice-weekly subcutaneous Etanercept （25mg） atTuesday and Friday, course of treatment is12weeks. The difference of the level ofserum TL1A, IL-17and the other data of laboratory and clinical pre-treatment andpost-treatment was analyzed, clinical response was observed, tendency of illness was determined, adverse effects of drugs were evaluated. Clinical responses totherapy were assessed using disease activity （DAS28）（effective group DAS28≤5.1,invalid group DAS28>5.1）.The difference of the level of serum TL1A, IL-17andthe other clinical data in two groups patients was compared; the relationshipbetween these clinical data and efficacy of Etanercept was evaluated. The relevancebetween the level of serum TL1A, IL-17and the other data of clinical andlaboratory after Etanercept treatment was analyzed. Discuss the relationshipbetween the level of serum TL1A, IL-17and tendency of illness.3. Software SPSS18.0was used for data statistics.Results1. The level of serum TL1A and IL-17(1031.8±634pg·mL^-1and257.07±84.88pg·mL^-1, respectively) was significantly increased in RA patients compared withhealthy volunteers (309.46±59.64pg·mL^-1and116.12±35.31pg·mL^-1, respectively),the difference was statistically significant （P<0.05）. The laboratory and clinicaldata of RA patients were significantly elevated compared with healthy volunteers（P<0.01）. There was a positive correlation between the level of serum TL1A, IL-17and inflammatory markers as well as clinical data （P<0.05）, but no correlation withRF （P>0.05）.2. For effective group, the level of serum TL1A, IL-17and data of laboratory andclinical were significantly decreased compared with baseline after12weekstreatment with Etanercept （P<0.01）. For invalid group, the level of serum TL1Aand IL-17was also decreased, but no significant difference （P>0.05）, theinflammatory markers and clinical symptoms were no significantly improved.Conclusions1. The level of serum TL1A and IL-17was significantly increased in RA patientscompared with healthy volunteers. There was a positive correlation between thelevel of serum TL1A, IL-17and inflammatory markers as well as clinical data.2. Serum TL1A and IL-17levels can be objective indictors for disease activity of RA,and efficacy of Etanercept.